Literature DB >> 26125978

A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis.

Noah Gruber1, Yehuda Shoenfeld.   

Abstract

PURPOSE OF REVIEW: The cause of primary ovarian insufficiency (POI) is multifactorial. Known causes include external factors such as chemotherapy, radiotherapy, exposure to endocrine-disrupting chemicals, infections that lead to a permanent insult to the ovary, autoimmune conditions, and genetic causes. An association between the quadrivalent antihuman papilloma vaccine (HPV4) and POI was recently suggested. RECENT
FINDINGS: An increasing number of cases of POI post-HPV4 are being reported. Possible mechanisms for the suspected effect of HPV on female reproductive function are a toxic effect or an autoimmune response. The trigger could be the vaccine immunogen contents or the adjuvants, the latter are used to increase the immune reaction. The adjuvant in HPV4 contains aluminum. Animal models have shown aluminum exposure to inhibit expression of female reproductive hormones and to induce histologic changes in the ovaries. Specific genetic compositions may be more susceptible to developing an autoinflammatory syndrome after exposure to an environmental factor.
SUMMARY: The mechanisms responsible for POI are not yet fully understood. Although case reports cannot establish causation, awareness of a possible link between HPV4 and POI will help to identify and manage future cases that may arise.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26125978     DOI: 10.1097/GCO.0000000000000183

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  7 in total

Review 1.  Addressing HPV vaccine myths: practical information for healthcare providers.

Authors:  Robert A Bednarczyk
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

Review 2.  Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity.

Authors:  Abdulla Watad; Paula David; Stav Brown; Yehuda Shoenfeld
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-24       Impact factor: 5.555

3.  Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.

Authors:  David A Geier; Mark R Geier
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.

Authors:  Matti Lehtinen; Tiina Eriksson; Dan Apter; Mari Hokkanen; Kari Natunen; Jorma Paavonen; Eero Pukkala; Maria-Genalin Angelo; Julia Zima; Marie-Pierre David; Sanjoy Datta; Dan Bi; Frank Struyf; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2016-12       Impact factor: 3.452

Review 5.  Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency.

Authors:  Alba M Polonio; Juan A García-Velasco; Sonia Herraiz
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

6.  Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort.

Authors:  Anders Hviid; Emilia Myrup Thiesson
Journal:  JAMA Netw Open       Date:  2021-08-02

Review 7.  Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee.

Authors:  Nadja Taumberger; Elmar A Joura; Marc Arbyn; Maria Kyrgiou; Jalid Sehouli; Murat Gultekin
Journal:  Int J Gynecol Cancer       Date:  2022-07-12       Impact factor: 4.661

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.